H.C. Wainwright lowered the firm’s price target on Orchestra BioMed (OBIO) to $12 from $14 and keeps a Buy rating on the shares following the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- OBIO Upcoming Earnings Report: What to Expect?
- Orchestra BioMed initiated with a Buy at BTIG
- Promising Clinical Developments and Strategic Advancements Drive Buy Rating for Orchestra BioMed Holdings
- Orchestra BioMed Highlights Strategic Initiatives and Innovations
- Orchestra BioMed Updates Executive Compensation Policies